The latest news, views and analysis from the pharmaceutical industry’s frontline in the war on cancer. Updates on pharmaceutical and biotech oncology pipelines, regulatory decisions and market access news, and how healthcare systems needs to change to tackle one of the world’s biggest killers.
FDA hands out new indications for Tecentriq and Lucentis.
MSD keeps pressure on BMS with EU classical Hodgkin lymphoma indication.
Novartis’ head of drug development talks about its stake in CAR-T immunotherapy. These cell therapies are set to transform treatment of blood cancers – but questions about safety, manufacturing and cost versus clinical value remain
Evaluate predicts sales could approach $8bn if approved.
Drug tops list compiled by Evaluate Pharma
Alecensa part of Roche’s goal of becoming dominant player in NSCLC